First-in-human, Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) Alone or in Combination With Pembrolizumab in Stage II– III Triple Negative Breast Cancer Following Standard Therapy ( VITAL-TNBC )

By clinicaltrials.govJune 17, 2026Updated:June 18, 2026No Comments1 Min Read